Servier Completes the Acquisition of Symphogen
PR84225
PARIS, June 4, 2020 /PRNewswire=KYODO JBN/ --
Servier, an independent international pharmaceutical company, today announced
that it has completed the acquisition of Symphogen A/S.
Symphogen will now function as Servier’s antibody center of excellence across
multiple different therapeutic areas, including oncology. Symphogen, now a
Servier subsidiary, will keep its operational autonomy and continue to rely on
its experienced employees while maintaining its headquarters in Ballerup,
Denmark.
As part of the acquisition, Christophe Thurieau, Executive Director of Servier
Research Institute, has been appointed Chief Executive Officer of Symphogen and
Karin Garre, former Chief Operating Officer of Symphogen, has been appointed
General Manager of Symphogen. Martin Olin, former Chief Executive Officer of
Symphogen, will act as an external consultant to support this transition.
Claude Bertrand, Executive Vice-President Research & Development at Servier,
said: "The completion of this acquisition enables Servier to boost its antibody
capabilities in oncology and its other therapeutic areas. The efficient
antibody discovery and research platform of Symphogen will strengthen our R&D
capabilities and pipeline in line with our aim of making life-saving treatments
available to more patients across the world."
Christophe Thurieau, Executive Director of Servier Research Institute and Chief
Executive Officer of Symphogen, added: "In line with the values of Symphogen,
we also strongly believe that innovation and collaboration are key to develop
treatments for the benefit of patients. We are very pleased to welcome
Symphogen as part of the Servier Group and look forward to further
collaborating with the team on developing breakthrough antibody therapies for
patients."
Karin Garre, General Manager of Symphogen, concluded: "The completion of this
transaction marks a very exciting journey for Symphogen and Servier. Anchored
in a pre-existing strategic collaboration, this acquisition supports the R&D
strategy of Servier within antibodies thanks to the capabilities of Symphogen.
As the two organizations share key values, I believe this unification is
positioned for a great outcome going forward."
PDF: https://mma.prnewswire.com/media/1175338/Servier_PDF_EN.pdf
Logo: https://mma.prnewswire.com/media/1175327/Servier_Logo.jpg
Contact:
Sonia Marques, presse@servier.com, Tel. +33(0)1-55-72-40-21 /
+33(0)7-84-28-76-13.
Jean-Clément Vergeau, presse@servier.com, Tel. +33(0)1-55-72-46-16 /
+33(0)6-79-56-75-96.
Source: Servier
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。